Deep-Vein Thrombosis
5
0
0
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
4 treatments under study, led by 5 Mg Folic Acid 50 Mg Pyridoxine And 04 Mg Cyanocobalamin
Research Leaders
8 sponsors active, led by Ottawa Hospital Research Institute
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 5 trials
100.0%
+13.4% vs benchmark
20%
1 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (5)
Implementing a Tool to Identify Risk for Venous Thromboembolism in Cancer Patients
Pro-coagulant Markers and Anticoagulant Failure in Cancer Patients at Risk for Recurrence of Venous Thromboembolism
Treatment of Upper Extremity Deep-Vein Thrombosis
Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study
VITRO-Trial. B Vitamins and the Secondary Prevention of Venous Thrombosis
Research Network
Common Treatments
- 5 Mg Folic Acid 50 Mg Pyridoxine And 04 Mg Cyanocobalamin1
- Warfarin1
- Apixaban1
- Dalteparin Sodium1
Active Sponsors
- Ottawa Hospital Research Institute2
- Radboud University Medical Center1
- Pfizer1
- Netherlands Heart Foundation1
- University of Oklahoma1
Top Investigators
Ottawa Hospital Research Institute
Maastricht University Medical Center
University of Oklahoma Health Science Center, Dept of Medicine/CardioVascular section
Radboud University Medical Center
Related Conditions
- Pulmonary Embolism3
- Venous Thromboembolism2
- Cancer2